• When it comes to Vascepa expansion, 'we can do this on our own' fiercepharma
    August 01, 2019
    Amarin’s fish-oil derivative Vascepa has been on a tear lately with a landmark outcomes trial and a $400 million cash raise in its rearview mirror. But taking the drug across the blockbuster plateau could present a challenge for a drugmaker as small as Am
PharmaSources Customer Service